Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Kezar Life Sciences Inc (KZR)

Kezar Life Sciences Inc (KZR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Kezar Life Sciences Reports Third Quarter 2025 Financial Results Business Wire - Wed Nov 12, 3:01PM CST

Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results...

KZR : 6.26 (-0.63%)
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 Business Wire - Fri Nov 7, 6:01AM CST

Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two...

KZR : 6.26 (-0.63%)
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives Business Wire - Thu Oct 16, 3:05PM CDT

Kezar Life Sciences, Inc . (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today...

KZR : 6.26 (-0.63%)
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences Business Wire - Thu Aug 28, 3:01PM CDT

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris...

KZR : 6.26 (-0.63%)
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update Business Wire - Wed Aug 13, 3:01PM CDT

  Announced FDA removal of partial clinical hold on PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis ...

KZR : 6.26 (-0.63%)
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis Business Wire WWW - Tue Jul 15, 3:41PM CDT

Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that...

KZR : 6.26 (-0.63%)
Karora Announces Agreement with Kalamazoo Resources to Unlock Lithium Exploration Value Through Creation of Kali Metals Limited Newswire.ca - Mon May 8, 2023

/CNW/ - Karora Resources Inc. (TSX: KRR) ("Karora" or the "Corporation") is pleased to announce it has entered into an agreement with Kalamazoo Resources...

KZR : 6.26 (-0.63%)
KZR.AX : 0.200 (-2.44%)
KRR.TO : 6.70 (+2.45%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire - Wed Apr 5, 2023

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 6.26 (-0.63%)
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update Business Wire - Tue Mar 14, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial...

KZR : 6.26 (-0.63%)
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023 Business Wire - Mon Mar 13, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the...

KZR : 6.26 (-0.63%)

Barchart Exclusives

Beyond Nvidia: The AI Stock to Buy With 205% Upside Potential Barchart - 13 minutes ago
Beyond chips, the real AI opportunity lies in who runs them best. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot